# LILRB2 (ILT4)

Source: https://onco.cc/targets/lilrb2/  
OnCo record `lilrb2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LILRB2 is a brake on monocytes and dendritic cells that reads HLA-G and other HLA class I molecules and keeps them in a tolerant, tumour-friendly state. The antibody MK-4830 blocks it and is in phase 2 with pembrolizumab.

## Summary

LILRB2 (chromosome 19q13.42) is a receptor for class I MHC antigens across HLA-A, B, C, G and F that is involved in down-regulating the immune response and developing tolerance, and recognises peptide-bound HLA-G with beta-2 microglobulin; it is expressed in monocytes, at lower levels in myeloid and plasmacytoid dendritic cells, in tolerogenic IL-10-producing dendritic cells, in myeloid-derived suppressor cells during pregnancy, at low levels in NK cells and in B cells (UniProt Q8N423). MK-4830 is in phase 2 studies with pembrolizumab, including a completed study with chemotherapy in ovarian cancer (NCT05446870) and a platform study in solid tumours (NCT04895722).

## Fields

- Kind: Target
- Last checked: 2026-09-24
- Also known as: ILT4; LIR-2; CD85d; leukocyte immunoglobulin like receptor B2
- Tags: checkpoint-map
- Symbol: LILRB2
- Class: checkpoint
- Biology: An ITIM-bearing LILR of myeloid cells; the murine orthologue PIRB regulates myeloid-derived suppressor cell development and a tumour-permissive microenvironment (van der Touw et al. 2017).
- Where found: Monocytes, dendritic cells, myeloid-derived suppressor cells (UniProt Q8N423); Ovarian cancer trial of MK-4830 (NCT05446870)

## Notes

- Prevalence not recorded: HGNC and UniProt carry no positivity rates.

## Sources

- HGNC HGNC:6606: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6606
- UniProt Q8N423: https://www.uniprot.org/uniprotkb/Q8N423/entry
- NCBI Gene 10288: https://www.ncbi.nlm.nih.gov/gene/10288
- ClinicalTrials.gov NCT05446870: https://clinicaltrials.gov/study/NCT05446870
- van der Touw et al. 2017 (Europe PMC): https://europepmc.org/article/MED/28638976

## Connected records

- targets: [HLA-A](https://onco.cc/targets/hla-a/), [LILRB1 (ILT2)](https://onco.cc/targets/lilrb1/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- pathways: [The cancer-immunity cycle](https://onco.cc/pathways/cancer-immunity-cycle/)
- terms: [Checkpoint (two meanings)](https://onco.cc/terms/checkpoint/)

---
JSON: https://onco.cc/api/v1/entities/lilrb2.json